#ESHCML2021 MEET THE EXPERT SESSIONS: REGISTRATION NOW OPEN!

23^rd ANNUAL JOHN GOLDMAN CONFERENCE ON
CHRONIC MYELOID LEUKEMIA:
BIOLOGY AND THERAPY

October 7-10, 2021 - E-CONFERENCE

---

ABOUT THE MEET THE EXPERT SESSIONS

The 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy Meet the Expert sessions are live, interactive sessions that offer you an opportunity for informal dialogue with world authorities. The number of seats available is strictly limited, first come-first serve*. The sessions will not be recorded.
There will be no formal presentation: WE INVITE YOU TO BRING A CLINICAL CASE. The Session Leaders are present to answer your questions and to provide you with expert guidance.

Registration Fee: 20 euros
*These sessions are open to academic biologists and clinicians only.

---

ABOUT THE E-CONFERENCE

E-Conference Chairpersons: Jorge Cortes, Tim P. Hughes, Daniela S. Krause

Co-organizers: Ravi Bhatia, Tim Brümmendorf, Mhairi Copland, Michael Deininger, Olivier Hantschel, François-Xavier Mahon, Danilo Perrotti, Jerry Radich, Delphine Réa

Advisory Committee: Jane Apperley, Susan Branford, Carlo Gambacorti-Passerini, François Guilhot, Rüdiger Hehlmann, Pierre Laneuville, Giuseppe Saglio, Charles Schiffer, Simona Soverini, Peter Valent, Rick Van Etten

JOIN US ONLINE ON
OCTOBER 7th, 2021 at 14:00 CEST
FOR THE LIVE PROGRAM

 

REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.

---

TIMING OF THE SCIENTIFIC PROGRAM:

Participants will be joining us from all over the world and from different time zones.
To make sure that everyone has access to the full scientific program at a convenient hour,
registration will allow participants to join both
the LIVE PROGRAM(October 7-10, 2021) and
the PROGRAM ON DEMAND (September 27 - November 10, 2021).

The “Live Program”
will be streamed live CEST time.
It will include Meet the Expert sessions, interactive panel discussions, Q&A periods and Mentored Poster Walks. It will also include some pre-recorded lectures that will be streamed live, followed by their corresponding fully live Q&A period.
Click here to access the updated program

The “Program on Demand”
will be available as of September 27, 2021.
It will initially include the pre-recorded components of the scientific program.
It will be progressively enriched by the meeting’s live, interactive components which will be recorded real time during the meeting.

E-POSTERS:
September 27 - November 10, 2021
The Poster Hall will also remain open until November 10, 2021.
The Mentored Poster Walks scheduled in the LIVE PROGRAM will also become available in the PROGRAM ON DEMAND.

VIRTUAL EXHIBITION:
September 27 - November 10, 2021
We invite you to visit the Exhibition area as ofSeptember 27.
Our corporate partners will be pleased to welcome & chat with you.

ABOUT THE PROGRAM:
Speakers at this meeting will present the newest and often unpublished data relating to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.

The program will include:
- John Goldman Prize Lecture
- Janet Rowley Prize Lecture
- iCMLf Prize Lecture
- ESH John Goldman International Research Award presentations
- Keynote lectures
- Special lectures
- Oral communications selected from submitted abstracts
- Workshops for non-clinical scientists
- Meet-the-Expert Sessions
- Clinical and Biology manned poster walks
- Special Clinical Symposium 2021

Educational Objectives:
Upon completion of this CME activity, participants should be able to:
1. Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.
2. Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.
3. Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.
4. Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.
5. Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.
6. Assess the role of allogeneic stem cell transplantation in the management of CML.
7. Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.
8. Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.
9. Discuss patient reported outcomes and their role in the management of patients with CML.

MORE INFORMATION

---

Join us on the 2021 Run.Ride.Cure challenge - Let's move towards a cure for CML Choose between three different options to support the Run.Ride.Cure challenge: 1. Register for the challenge and raise funds 2. Get your Run.Ride.Cure charity t-shirt 3. Donate to the Run.Ride.Cure campaign Learn more about Run.Ride.Cure 2021 and get involved...

           

---

---

With the support of*:

       

Emerald E-Conference Partners
******

Ruby E-Conference Partner
******

 

*ESH conference programs are developed in strict scientific independence
with no input from corporate sponsors.